Suparna Wedam

2.1k total citations
30 papers, 1.4k citations indexed

About

Suparna Wedam is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Suparna Wedam has authored 30 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Oncology, 16 papers in Cancer Research and 12 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Suparna Wedam's work include Cancer Treatment and Pharmacology (14 papers), Breast Cancer Treatment Studies (14 papers) and Advanced Breast Cancer Therapies (10 papers). Suparna Wedam is often cited by papers focused on Cancer Treatment and Pharmacology (14 papers), Breast Cancer Treatment Studies (14 papers) and Advanced Breast Cancer Therapies (10 papers). Suparna Wedam collaborates with scholars based in United States, Spain and Switzerland. Suparna Wedam's co-authors include Laleh Amiri‐Kordestani, Richard Pazdur, Sandra M. Swain, Seth M. Steinberg, Erik Bloomquist, Rajeshwari Sridhara, Jennifer A. Low, Arlene Berman, Sherry X. Yang and Julia A. Beaver and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Radiology.

In The Last Decade

Suparna Wedam

27 papers receiving 1.4k citations

Peers

Countries citing papers authored by Suparna Wedam

Since Specialization

Citations

This map shows the geographic impact of Suparna Wedam's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Suparna Wedam with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Suparna Wedam more than expected).

Fields of papers citing papers by Suparna Wedam

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Suparna Wedam. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Suparna Wedam. The network helps show where Suparna Wedam may publish in the future.

Co-authorship network of co-authors of Suparna Wedam

This figure shows the co-authorship network connecting the top 25 collaborators of Suparna Wedam. A scholar is included among the top collaborators of Suparna Wedam based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Suparna Wedam. Suparna Wedam is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	US Food and Drug Administration Approval Summary: Inavolisib With Palbociclib and Fulvestrant for Endocrine-Resistant, PIK3CA -Mutated, Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative, Locally Advanced or Metastatic Breast Cancer 2025 ·Journal of Clinical Oncology ·Suparna Wedam, Preeti Narayan, Haley Gittleman, Joyce Cheng, (unknown), (unknown), Lauren Price, Nam Atiqur Rahman, Haw-Jyh Chiu, (unknown), Tiffany K. Ricks, Mallorie H. Fiero, Shenghui Tang, Christy Osgood, William F. Pierce, Richard Pazdur, Paul G. Kluetz, Laleh Amiri‐Kordestani	1
2	U.S. FDA analysis of enrollment of Asian patients from India in cancer clinical trials leading to approval from 2010 to 2022. 2024 ·Journal of Clinical Oncology ·Geetika Srivastava, Rupert W. Leong, Abhilasha Nair, Bindu Kanapuru, Fatima Rizvi, (unknown), Jennifer J. Lee, Suparna Wedam, Asma Dilawari, (unknown), (unknown), (unknown), Clara Lee, Donna R. Rivera, Steven J. Lemery, Jennifer Gao, Tamy Kim, Richard Pazdur	1
3	Underrepresentation of Asian Americans, Native Hawaiians, and other Pacific Islanders (AA & NHPI) in cancer clinical trials that led to FDA approvals in 2010-2022. 2024 ·Journal of Clinical Oncology ·Rupert W. Leong, (unknown), Jennifer J. Lee, Geetika Srivastava, Suparna Wedam, Asma Dilawari, (unknown), (unknown), (unknown), (unknown), Clara Lee, Lola A. Fashoyin‐Aje, Laleh Amiri‐Kordestani, Harpreet Singh, Steven J. Lemery, Richard Pazdur, Donna R. Rivera, Jennifer Gao, Tamy Kim	1
4	Overall survival in patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer treated with a cyclin-dependent kinase 4/6 inhibitor plus fulvestrant: a US Food and Drug Administration pooled analysis 2021 ·The Lancet Oncology ·Jennifer Gao, Joyce Cheng, Tatiana M. Prowell, Erik Bloomquist, Shenghui Tang, Suparna Wedam, Melanie Royce, (unknown), Christy Osgood, Gwynn Ison, Rajeshwari Sridhara, Richard Pazdur, Julia A. Beaver, Laleh Amiri‐Kordestani	21
5	US Food and Drug Administration regulatory updates in neuro-oncology 2021 ·Journal of Neuro-Oncology ·Gautam U. Mehta, Amy Barone, Diana Bradford, Erin Larkins, (unknown), Lee H. Pai-Scherf, (unknown), Mirat Shah, Suparna Wedam, Laleh Amiri‐Kordestani, Marc R. Theoret, Richard Pazdur, Julia A. Beaver, Harpreet Singh	8
6	Model Development of CDK4/6 Predicted Efficacy in Patients With Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced or Metastatic Breast Cancer 2021 ·JCO Clinical Cancer Informatics ·Jeremy Mason, Yutao Gong, Laleh Amiri‐Kordestani, Suparna Wedam, Jennifer Gao, Tatiana M. Prowell, Harpreet Singh, Anup Amatya, Shenghui Tang, Richard Pazdur, Peter Kühn, Gideon M. Blumenthal, Julia A. Beaver	2
7	FDA Approval Summary: Ado-Trastuzumab Emtansine for the Adjuvant Treatment of HER2-positive Early Breast Cancer 2020 ·Clinical Cancer Research ·Suparna Wedam, Lola A. Fashoyin‐Aje, Xin Gao, Erik Bloomquist, Shenghui Tang, Rajeshwari Sridhara, Kirsten B. Goldberg, Bellinda L. King‐Kallimanis, Marc R. Theoret, Amna Ibrahim, Laleh Amiri‐Kordestani, Richard Pazdur, Julia A. Beaver	65
8	Abstract PD2-07: Prediction of CDK inhibitor efficacy in ER+/HER2- breast cancer using machine learning algorithms 2020 ·Cancer Research ·Jeremy Mason, Yutao Gong, Laleh Amiri‐Kordestani, Suparna Wedam, Jennifer Gao, Harpreet Singh, Richard Pazdur, Peter Kühn, Gideon M. Blumenthal, Julia A. Beaver	0
9	CDK4/6 inhibitor treatment for patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer: a US Food and Drug Administration pooled analysis 2019 ·The Lancet Oncology ·Jennifer Gao, Joyce Cheng, Erik Bloomquist, (unknown), Suparna Wedam, Harpreet Singh, Laleh Amiri‐Kordestani, Amna Ibrahim, Rajeshwari Sridhara, Kirsten B. Goldberg, Marc R. Theoret, Paul G. Kluetz, Gideon M. Blumenthal, Richard Pazdur, Julia A. Beaver, Tatiana M. Prowell	194
10	FDA Approval Summary: Palbociclib for Male Patients with Metastatic Breast Cancer 2019 ·Clinical Cancer Research ·Suparna Wedam, Lola A. Fashoyin‐Aje, Erik Bloomquist, Shenghui Tang, Rajeshwari Sridhara, Kirsten B. Goldberg, Marc R. Theoret, Laleh Amiri‐Kordestani, Richard Pazdur, Julia A. Beaver	102
11	US Food and Drug Administration Pooled Analysis to Assess the Impact of Bone-Only Metastatic Breast Cancer on Clinical Trial Outcomes and Radiographic Assessments 2018 ·Journal of Clinical Oncology ·Suparna Wedam, Julia A. Beaver, Laleh Amiri‐Kordestani, Erik Bloomquist, Shenghui Tang, Kirsten B. Goldberg, Rajeshwari Sridhara, Amna Ibrahim, Geoffrey Kim, Paul G. Kluetz, Amy S. McKee, Richard Pazdur	13
12	First FDA Approval of Neoadjuvant Therapy for Breast Cancer: Pertuzumab for the Treatment of Patients with HER2-Positive Breast Cancer 2014 ·Clinical Cancer Research ·Laleh Amiri‐Kordestani, Suparna Wedam, Lijun Zhang, Shenghui Tang, Amy Tilley, Amna Ibrahim, Robert Justice, Richard Pazdur, Patricia Cortazar	114
13	Neoadjuvant bevacizumab and chemotherapy in breast cancer 2012 ·Translational Cancer Research ·Suparna Wedam, Sherry Yang	3
14	Abstract P1-07-03: Effect of Exemestane on Mammographic Density in Postmenopausal Women at Risk for Breast Cancer 2010 ·Cancer Research ·Jennifer Eng‐Wong, David Venzon, (unknown), Claudine Isaacs, (unknown), Suparna Wedam, (unknown), Larissa A. Korde, Christopher D. Byrne	1
15	Inflammatory Breast Cancer: Dynamic Contrast-enhanced MR in Patients Receiving Bevacizumab—Initial Experience 2007 ·Radiology ·(unknown), David Thomasson, Catherine K. Chow, M. R. Garcia de Eulate, Suparna Wedam, Sandeep Gupta, (unknown), Seth M. Steinberg, David J. Liewehr, Peter L. Choyke, Sandra M. Swain	58
16	Neoadjuvant docetaxel followed by adjuvant doxorubicin and cyclophosphamide in patients with stage III breast cancer 2005 ·Annals of Oncology ·William J. Gradishar, Suparna Wedam, Mohammad Jahanzeb, John K. Erban, Steven Limentani, (unknown), Steven R. Olsen, Sandra M. Swain	32
17	Dynamic contrast enhanced MRI (DCE-MRI) as a potential predictor of clinical response in patients with inflammatory breast cancer (IBC) 2005 ·Journal of Clinical Oncology ·(unknown), Suparna Wedam, (unknown), M. R. Garcia de Eulate, (unknown), (unknown), S. M. Steinberg, (unknown), Peter L. Choyke, Sandra M. Swain	4
18	Phase II Clinical Trial of Ixabepilone (BMS-247550), an Epothilone B Analog, in Metastatic and Locally Advanced Breast Cancer 2005 ·Journal of Clinical Oncology ·Jennifer A. Low, Suparna Wedam, James J. Lee, Arlene Berman, Adam Brufsky, Sherry X. Yang, Marianne S. Poruchynsky, Seth M. Steinberg, (unknown), Tito Fojo, Sandra M. Swain	172
19	A pilot study to evaluate response and angiogenesis after treatment with bevacizumab in patients with inflammatory breast cancer 2004 ·Journal of Clinical Oncology ·Suparna Wedam, Jennifer A. Low, Xiao‐Sheng Yang, C. Chow, Arlene Berman, M. R. Garcia de Eulate, David N. Danforth, (unknown), (unknown), Sandra M. Swain	4
20	A phase 2 trial of BMS-247550 (ixabepilone), an epothilone B analog, given daily x 5 in breast cancer 2004 ·Journal of Clinical Oncology ·Jennifer A. Low, Suparna Wedam, Adam Brufsky, Andrea J. Berman, (unknown), (unknown), S. M. Steinberg, (unknown), Tito Fojo, Sandra M. Swain	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact